Refine by
Needleless Articles & Analysis
34 news found
Portal Instruments is pleased to announce the appointment of Dr. Veena Rao, PhD, as Chief Business Officer, effective December 5th, 2022. Dr. Rao will lead the identification, evaluation, and negotiation of partnership opportunities for Portal. In addition, Dr. Rao, in close collaboration with the CEO and cross-functional team, will guide the company’s short and long-term commercial ...
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced the publication of data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. The research, conducted in collaboration with the University of Washington, was published in the peer-reviewed journal, Nature Partner ...
Biolingus IP II GmbH and the CHA Vaccine Institute Co., Ltd., with support from the Korean biotech company PanGen Biotech Inc., will collaborate to develop a sublingual vaccine for COVID. The project has received research funding from The Research Investment for Global Health Technology Fund (The RIGHT Fund). The RIGHT Fund is a Public-Private Partnership (PPP) funding agency between the ...
Australian biotechnology company, Vaxxas Pty Ltd (Vaxxas), in collaboration with the University of Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, has completed a study assessing the usability and acceptability of its novel High-Density Microarray Patch (HD-MAP) to administer vaccines. The HD-MAP is Vaxxas’ proprietary vaccine patch technology, representing a ...
Gerresheimer AG is expanding its portfolio of highly-innovative platform technologies for drug delivery. Gerresheimer, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, today announced an investment into US-based Portal Instruments, a developer of a next-generation needle-free drug delivery technology. Together, the partners aim ...
Dermatologists may perform a number of in-office procedures that result in wounds, including biopsies and mole excisions. Traditional options for repairing these wounds include sutures, staples, adhesive strips, and other suture types. However, traditional wound care methods have several drawbacks, including cost, time, and patient limitations. New wound closure options, such as the microMend ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens, enabled by its ImplaVax® technologies, has entered into an agreement with the US National Institute of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to test a novel ...
Enesi Pharma Ltd (“Enesi”), an innovative biotechnology company developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its world leading ImplaVax® technologies, is delighted to announce the appointment of Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations. Ms. Eagling-Vose brings over 20 years’ ...
There are self-driving cars, 5G smartphones, and now planes that travel from New York to London in 3.5 hours. The world we live in and the technology we use are rapidly evolving. But, when it comes to drug delivery methods, the 160-year old technology behind the needle and syringe has yet to catch wind of any radical transformation. With cutting-edge technology from MIT, Portal Instruments aims ...
? Meissa’s intranasal recombinant live attenuated COVID-19 vaccine, MV-014-212, induced mucosal as well as systemic antibodies against SARS-CoV-2 and two variants of concern ? MV-014-212 was built on the company’s AttenuBlock platform and is designed to be appropriately attenuated, genetically stable, and optimized to drive robust, broad, and durable immunity ? Data will be ...
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious diseases and cancer conditions, today announces publication of key non-clinical proof-of-concept data on its lead vaccine candidate V-306 in two high quality peer-reviewed journals. The data confirm the potential of V-306 for ...
· No vaccine is currently approved to protect against respiratory syncytial virus (RSV) · RSV is the leading cause of infant hospitalization in the United States and is considered the “missing” pediatric vaccine · Previous clinical data in seropositive adult and pediatric participants showed MV-012-968 was well-tolerated, appropriately attenuated, and stimulated ...
The National Transgender Discrimination Survey Report on Health and Health Care recorded at least 80% of transgender people have either taken gender-affirming hormone therapy (GAHT) or want to take GAHT at some point.¹ We sat down to learn from Joelle Jacoski about the drug delivery challenges of taking GAHT. “I came out as non-binary about four months ago and ...
Enesi Pharma is pleased to acknowledge Lynette Eyb’s excellent article ‘A Total Meltdown’ in Medical Device Developments’ where the potential of Enesi’s proprietary ImplaVax® formulation and delivery technologies are discussed. The Article ‘A Total Meltdown‘ highlights how next generation vaccination technologies such as ImplaVax® needle-free, ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to report positive top-line results from a new study evaluating the immune responses generated by an ImplaVax®-enabled unit solid-dose formulation of classical ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella. ...
Innovative needle-free injectable unit solid-dose presentation of recombinant H7N9 pandemic flu vaccine, created using Enesi’s ImplaVax technology, generated immune responses comparable with liquid vaccine and demonstrated excellent thermal stability at temperatures up to 40°C for six months. Enesi Pharma (“Enesi”), an innovative biotechnology company developing ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces that its CEO, David Hipkiss will give a presentation at the upcoming World Vaccine Congress 2021 Virtual meeting (4-6 May 2021), which this year is free to attend. ...
Moffitt Cancer Center has adopted a new needle-free method of blood collection for patients in treatment who often need to undergo repeated needle sticks in a day, becoming the first cancer center in Florida to offer this pain-free technology as part of its world-class cancer care. In its continuing efforts of being at the forefront of innovation, last year the cancer center piloted the ...
Initial preclinical data shows MV-014-212 induced a SARS-CoV-2-specific mucosal IgA response, generated serum neutralizing antibodies, and provided efficacy against challenge REDWOOD CITY, Calif., March 16, 2021 – Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today that the company has ...